2004_CD SkyePharma_NNP Annual_JJ Report_NNP 21_CD International_NNP Financial_NNP Reporting_NNP Standards_NNPS The_DT 2004_CD consolidated_JJ financial_JJ statements_NNS have_VBP been_VBN prepared_VBN under_IN UK_NNP IAS_NNP 19_CD :_: Employee_NN benefits_NNS Generally_RB Accepted_JJ Accounting_NN Principles_NNPS UK_NNP GAAP_NNP ,_, SkyePharmas_NNP historic_JJ In_IN accordance_NN with_IN IFRS1_NNP ,_, the_DT Group_NNP expects_VBZ to_TO elect_VB to_TO fully_RB recognize_VB all_DT primary_JJ reporting_NN GAAP_NNP ._.
From_IN 1_CD January_NNP 2005_CD SkyePharma_NNP is_VBZ required_VBN to_TO actuarial_JJ gains_NNS and_CC losses_NNS on_IN its_PRP$ pension_NN scheme_NN in_IN France_NNP at_IN 1_CD January_NNP prepare_VB its_PRP$ consolidated_JJ financial_JJ statements_NNS under_IN International_NNP Financial_NNP 2004_CD ,_, its_PRP$ transition_NN date_NN to_TO IFRS_NNP ._.
Subject_JJ to_TO the_DT endorsement_NN by_IN the_DT Reporting_NNP Standards_NNPS IFRS_NNP ._.
These_DT standards_NNS represent_VBP a_DT significant_JJ change_NN European_NNP Union_NNP of_IN IAS_NNP 19_CD revised_VBN ,_, ongoing_JJ actuarial_JJ gains_NNS and_CC losses_NNS will_MD from_IN UK_NNP GAAP_NNP ._.
While_IN SkyePharmas_NNP first_RB published_VBD IFRS_NNP financial_JJ statements_NNS be_VB recognized_VBN in_IN the_DT Statement_NN of_IN Recognised_NNP Income_NNP and_CC Expenditure_NNP ._.
will_MD be_VB its_PRP$ interim_JJ results_NNS for_IN June_NNP 2005_CD ,_, guidance_NN is_VBZ provided_VBN below_RB as_IN to_TO the_DT key_JJ differences_NNS that_IN the_DT Group_NNP expects_VBZ to_TO arise_VB on_IN the_DT adoption_NN of_IN IFRS_NNP ._.
IAS_NNP 32_CD and_CC IAS_NNP 39_CD :_: Financial_NNP Instruments_NNP The_NNP Group_NNP intends_VBZ to_TO communicate_VB further_JJ details_NNS of_IN the_DT impact_NN of_IN adopting_VBG One_CD of_IN the_DT exemptions_NNS available_JJ under_IN IFRS1_NNP relaxes_VBZ the_DT requirement_NN IFRS_NNP on_IN the_DT 2004_CD results_NNS during_IN the_DT first_JJ half_NN of_IN 2005_CD ._.
to_TO present_VB comparative_JJ information_NN on_IN financial_JJ instruments_NNS for_IN 2004_CD in_IN the_DT 2005_CD financial_JJ statements_NNS ._.
The_DT Group_NNP does_VBZ not_RB anticipate_VB utilising_VBG Assumptions_NNS this_DT exemption_NN ,_, and_CC expects_VBZ to_TO retrospectively_RB apply_VB IAS_NNP 32_CD Financial_NNP The_DT financial_JJ impact_NN of_IN the_DT transition_NN to_TO IFRS_NNP has_VBZ been_VBN assessed_VBN based_VBN upon_IN Instruments_NNPS :_: Disclosure_NN and_CC presentation_NN and_CC IAS_NNP 39_CD Financial_NNP the_DT assumption_NN that_IN all_DT IFRS_NNP standards_NNS issued_VBN by_IN the_DT International_NNP Accounting_NNP Instruments_NNPS :_: Recognition_NN and_CC Measurement_NNP which_WDT for_IN many_JJ financial_JJ Standards_NNP Board_NNP IASB_NNP that_WDT are_VBP effective_JJ for_IN 2005_CD reporting_NN are_VBP endorsed_VBN instruments_NNS will_MD be_VB fair_JJ value_NN ._.
At_IN present_JJ ,_, the_DT European_JJ Commission_NNP has_VBZ not_RB endorsed_VBN all_DT of_IN these_DT standards_NNS ._.
Although_IN the_DT IASB_NNP has_VBZ issued_VBN all_DT standards_NNS IAS_NNP 21_CD :_: The_DT Effects_NNPS of_IN Changes_NNS in_IN Foreign_NNP Exchange_NNP Rates_NNP that_WDT will_MD be_VB compulsory_JJ for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD ,_, some_DT new_JJ An_DT exemption_NN offered_VBN by_IN IFRS_NNP 1_CD in_IN respect_NN of_IN IAS_NNP 21_CD The_DT Effects_NNPS of_IN standards_NNS may_MD be_VB available_JJ for_IN early_JJ adoption_NN ,_, changes_NNS are_VBP still_RB anticipated_VBN Changes_NNS in_IN Foreign_NNP Exchange_NNP Rates_NNP gives_VBZ the_DT Group_NNP the_DT option_NN to_TO reset_VB to_TO others_NNS and_CC the_DT interpretation_NN and_CC application_NN of_IN certain_JJ recently_RB revised_VBN its_PRP$ cumulative_JJ translation_NN differences_NNS to_TO zero_CD at_IN 1_CD January_NNP 2004_CD ,_, its_PRP$ date_NN standards_NNS is_VBZ still_RB being_VBG debated_VBN ._.
Therefore_RB the_DT current_JJ position_NN with_IN respect_NN of_IN transition_NN ._.
The_DT Group_NNP does_VBZ not_RB expect_VB to_TO take_VB this_DT exemption_NN ,_, and_CC will_MD to_TO IFRS_NNP may_MD be_VB subject_JJ to_TO change_VB ._.
continue_VB to_TO include_VB its_PRP$ cumulative_JJ translation_NN differences_NNS within_IN equity_NN ._.
This_DT is_VBZ because_IN the_DT information_NN is_VBZ readily_RB available_JJ and_CC will_MD be_VB consistent_JJ Transition_NN Date_NNP and_CC Comparative_NNP Information_NNP with_IN its_PRP$ reporting_NN under_IN US_NNP GAAP_NNP ._.
The_DT IASB_NNP issued_VBD IFRS_NNP 1_CD First_JJ time_NN adoption_NN of_IN international_JJ financial_JJ reporting_NN standards_NNS in_IN June_NNP 2003_CD ._.
This_DT deals_VBZ with_IN how_WRB companies_NNS will_MD have_VB to_TO apply_VB Key_NNP differences_NNS IFRS_NNP for_IN the_DT first_JJ time_NN ._.
IFRS_NNS 1_CD requires_VBZ that_IN comparative_JJ information_NN be_VB The_DT key_JJ differences_NNS that_IN the_DT Group_NNP expects_VBZ to_TO arise_VB on_IN the_DT adoption_NN restated_VBN for_IN all_DT years_NNS that_IN a_DT full_JJ set_NN of_IN comparatives_NNS is_VBZ provided_VBN ._.
Therefore_RB ,_, of_IN IFRS_NNP are_VBP :_: the_DT Groups_NNS IFRS_VBP transition_NN date_NN is_VBZ 1_CD January_NNP 2004_CD ._.
revenue_NN recognition_NN differences_NNS in_IN respect_NN of_IN up_RB front_JJ payments_NNS :_: IFRS_NNS 1_CD Exemptions_NNS accounting_VBG for_IN the_DT sale_NN of_IN royalty_NN interests_NNS to_TO Paul_NNP Capital_NNP :_: In_IN general_JJ a_DT Group_NNP is_VBZ required_VBN to_TO determine_VB its_PRP$ IFRS_NNP accounting_NN policies_NNS and_CC the_DT inclusion_NN of_IN a_DT fair_JJ value_NN charge_NN in_IN respect_NN of_IN outstanding_JJ employee_NN apply_VB these_DT retrospectively_RB to_TO determine_VB its_PRP$ opening_VBG balance_NN sheet_NN ,_, in_IN our_PRP$ case_NN share_NN options_NNS :_: at_IN 1_CD January_NNP 2004_CD ,_, under_IN IFRS_NNP at_IN its_PRP$ transition_NN date_NN ._.
However_RB IFRS_NNP 1_CD permits_VBZ the_DT cessation_NN of_IN amortisation_NN of_IN goodwill_NN :_: those_DT companies_NNS adopting_VBG IFRS_NNP for_IN the_DT first_JJ time_NN to_TO take_VB some_DT exemptions_NNS accounting_VBG for_IN convertible_JJ bonds_NNS :_: and_CC from_IN the_DT full_JJ requirements_NNS of_IN IFRS_NNP in_IN the_DT transition_NN period_NN ._.
the_DT capitalization_NN of_IN certain_JJ research_NN and_CC development_NN costs_NNS ._.
The_DT key_JJ IFRS_NNP 1_CD transitional_JJ provisions_NNS the_DT Group_NNP proposes_VBZ to_TO adopt_VB are_VBP Revenue_NN Recognition_NN outlined_VBN below_IN ._.
Under_IN IFRS_NNP SkyePharma_NNP will_MD adopt_VB a_DT revenue_NN recognition_NN policy_NN in_IN accordance_NN with_IN IAS_NNP 18_CD which_WDT is_VBZ similar_JJ to_TO that_DT applied_VBN under_IN US_NNP GAAP_NNP ._.
Under_IN UK_NNP GAAP_NNP IFRS_VBZ 3_CD :_: Business_NNP combinations_NNS Skye_NNP has_VBZ generally_RB recognized_VBN up_RP front_JJ payments_NNS immediately_RB in_IN full_JJ where_WRB A_DT first_JJ time_NN adopter_NN has_VBZ the_DT option_NN not_RB to_TO restate_VB most_JJS aspects_NNS of_IN past_JJ there_EX are_VBP no_DT material_NN future_NN obligations_NNS and_CC the_DT milestones_NNS are_VBP nonbusiness_NN combinations_NNS and_CC instead_RB to_TO apply_VB IFRS_NNP 3_CD prospectively_RB from_IN the_DT refundable_JJ ,_, on_IN the_DT basis_NN that_IN the_DT up_RP front_NN is_VBZ a_DT payment_NN for_IN past_JJ services_NNS ._.
It_PRP is_VBZ expected_VBN that_IN SkyePharma_NNP will_MD elect_VB this_DT option_NN ._.
In_IN this_DT Under_IN IFRS_NNP generally_RB up_RB front_JJ payments_NNS will_MD be_VB deferred_VBN and_CC amortised_VBN case_NN goodwill_NN would_MD remain_VB largely_RB as_IN under_IN UK_NNP GAAP_NNP and_CC amortisation_NN on_IN a_DT systematic_JJ basis_NN over_IN the_DT period_NN of_IN development_NN to_TO filing_NN ._.
This_DT is_VBZ similar_JJ would_MD stop_VB at_IN 1_CD January_NNP 2004_CD ,_, SkyePharmas_NNP proposed_VBD transition_NN date_NN ._.
to_TO the_DT treatment_NN adopted_VBN under_IN US_NNP GAAP_NNP ._.
However_RB ,_, the_DT accounting_NN for_IN each_DT agreement_NN will_MD need_VB to_TO be_VB determined_VBN on_IN an_DT individual_JJ basis_NN ._.
IFRS_NNS 2_CD :_: Share_NN based_VBN payments_NNS IFRS_VBP 2_CD applies_VBZ to_TO unvested_JJ equity_NN instruments_NNS ,_, such_JJ as_IN share_NN options_NNS ,_, Sale_NNP of_IN Royalty_NNP Interests_NNPS granted_VBD since_IN 7_CD November_NNP 2002_CD and_CC not_RB vested_VBN at_IN 1_CD January_NNP 2005_CD ._.
However_RB Under_IN IFRS_NNP SkyePharma_NNP will_MD account_VB for_IN the_DT sale_NN of_IN royalty_NN interests_NNS to_TO Paul_NNP under_IN the_DT transitional_JJ arrangements_NNS of_IN IFRS_NNP 1_CD ,_, there_EX is_VBZ the_DT option_NN to_TO adopt_VB Capital_NN on_IN a_DT similar_JJ basis_NN to_TO that_DT under_IN US_NNP GAAP_NNP ._.
Under_IN IFRS_NNP the_DT proceeds_NNS full_JJ retrospective_NN application_NN of_IN the_DT standard_NN where_WRB companies_NNS have_VBP received_VBN from_IN Paul_NNP Capital_NNP meet_VBP the_DT definition_NN of_IN a_DT financial_JJ liability_NN under_IN IAS_NNP previously_RB publicly_RB disclosed_VBN the_DT fair_JJ value_NN of_IN those_DT equity_NN instruments_NNS 32_CD ,_, and_CC will_MD be_VB treated_VBN as_IN debt_NN ._.
No_DT other_JJ operating_NN income_NN will_MD be_VB recognized_VBN determined_VBN at_IN the_DT measurement_NN date_NN ._.
SkyePharma_NNP has_VBZ previously_RB disclosed_VBN under_IN IFRS_NNP ,_, royalties_NNS paid_VBD to_TO Paul_NNP Capital_NNP will_MD be_VB treated_VBN as_IN repayment_NN of_IN the_DT those_DT fair_JJ values_NNS in_IN its_PRP$ US_NNP GAAP_NNP disclosures_NNS and_CC expects_VBZ to_TO adopt_VB full_JJ debt_NN and_CC interest_NN will_MD be_VB charged_VBN on_IN the_DT debt_NN ._.
Under_IN UK_NNP GAAP_NNP the_DT proceeds_NNS retrospective_JJ application_NN ._.
received_VBN from_IN Paul_NNP Capital_NNP are_VBP treated_VBN as_IN a_DT sale_NN and_CC recorded_VBN as_IN other_JJ operating_NN income_NN and_CC royalties_NNS are_VBP expensed_VBN when_WRB incurred_VBN ._.
22_CD SkyePharma_NNP Annual_JJ Report_NNP 2004_CD International_NNP Financial_NNP Reporting_NNP Standards_NNPS continued_VBD Share_NN Based_VBN Payments_NNS IFRS_VBP 2_CD requires_VBZ that_IN for_IN share_NN option_NN awards_NNS to_TO employees_NNS ,_, the_DT fair_JJ value_NN of_IN the_DT employee_NN services_NNS received_VBD should_MD be_VB measured_VBN by_IN reference_NN to_TO the_DT fair_JJ value_NN of_IN the_DT share_NN option_NN at_IN the_DT grant_NN date_NN ._.
This_DT is_VBZ significantly_RB different_JJ from_IN the_DT current_JJ treatment_NN in_IN the_DT UK_NNP where_WRB the_DT charge_NN to_TO the_DT profit_NN and_CC loss_NN account_NN is_VBZ based_VBN on_IN the_DT difference_NN between_IN the_DT fair_JJ value_NN of_IN the_DT shares_NNS at_IN the_DT date_NN of_IN grant_NN and_CC the_DT exercise_NN price_NN ._.
Since_IN SkyePharma_NNP has_VBZ historically_RB granted_VBN employee_NN options_NNS where_WRB the_DT share_NN price_NN at_IN the_DT date_NN of_IN grant_NN equals_VBZ the_DT exercise_NN price_NN ,_, there_EX has_VBZ been_VBN no_DT charge_NN to_TO record_NN ._.
The_DT charge_NN under_IN IFRS_NNP will_MD be_VB the_DT same_JJ as_IN that_DT previously_RB disclosed_VBN under_IN US_NNP GAAP_NNP standard_JJ FAS_NNP 123_CD ._.
Goodwill_NNP Amortisation_NNP UK_NNP GAAP_NNP requires_VBZ goodwill_NN to_TO be_VB amortised_VBN over_IN its_PRP$ estimated_VBN expected_VBN useful_JJ life_NN which_WDT the_DT Directors_NNS have_VBP determined_VBN is_VBZ 20_CD years_NNS ._.
Under_IN IFRS_NNP ,_, goodwill_NN is_VBZ considered_VBN to_TO have_VB an_DT indefinite_JJ life_NN and_CC so_RB is_VBZ not_RB amortised_VBN ,_, but_CC is_VBZ subject_JJ to_TO annual_JJ impairment_NN testing_NN ._.
Therefore_RB the_DT annual_JJ goodwill_NN charge_NN made_VBN under_IN UK_NNP GAAP_NNP will_MD not_RB be_VB recorded_VBN under_IN IFRS_NNP from_IN 1_CD January_NNP 2004_CD ,_, the_DT IFRS_NNP transition_NN date_NN ._.
Convertible_JJ Bond_NN Under_IN UK_NNP GAAP_NNP the_DT net_JJ proceeds_NNS of_IN the_DT convertible_JJ bond_NN issue_NN were_VBD recorded_VBN as_IN debt_NN ._.
Under_IN IFRS_NNP the_DT convertible_JJ bonds_NNS will_MD be_VB bifurcated_VBN and_CC the_DT conversion_NN option_NN deducted_VBN from_IN the_DT debt_NN and_CC classified_VBN as_IN equity_NN ._.
This_DT will_MD lead_VB to_TO higher_JJR interest_NN charges_NNS under_IN IFRS_NNP than_IN under_IN UK_NNP GAAP_NNP ._.
Furthermore_RB the_DT Group_NNP is_VBZ likely_JJ to_TO record_VB a_DT one_CD off_RP gain_NN or_CC loss_NN on_IN the_DT exchange_NN of_IN the_DT 2005_CD bonds_NNS for_IN the_DT 2024_CD bonds_NNS ._.
No_DT such_JJ gain_NN or_CC loss_NN arises_VBZ under_IN UK_NNP GAAP_NNP ._.
Research_NNP and_CC Development_NNP Under_IN IFRS_NNP the_DT Group_NNP is_VBZ required_VBN to_TO capitalize_VB research_NN and_CC development_NN when_WRB the_DT criteria_NNS as_IN laid_VBN out_RP in_IN IAS_NNP 38_CD are_VBP met_VBN ._.
The_DT Group_NNP has_VBZ reviewed_VBN its_PRP$ current_JJ projects_NNS and_CC determined_VBD that_IN the_DT capitalization_NN of_IN certain_JJ expenditure_NN may_MD be_VB appropriate_JJ ._.
Future_JJ projects_NNS may_MD lead_VB to_TO the_DT capitalization_NN of_IN further_JJ expenditure_NN ._.
